Sudarshan Pharma Industries Ltd.

BSE: 543828

Sudarshan Pharma Live Share Price Today, Share Analysis and Chart

Name: Sudarshan Pharma Industries Ltd.: Is Infosys Ltd. worth buying?
Item: Sudarshan Pharma Industries Ltd.
Rating: 2.05025
Author: Trendlyne DVM scores

Await Turnaround

aboutSudarshan Pharma Industries Ltd. is an integrated pharmaceutical organization primarily engaged in the manufacturing and supply of specialty chemicals, intermediates, and Active Pharmaceutical Ingredients (APIs). The company operates across the pharm... Read More

-0.46(-1.28%)

91.24% Gain from 52W Low

137.1K

NSE+BSE Volume

BSE 02 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Durability score

- / 100

Valuation Score

- / 100

Momentum Score

56.0 / 100

Await TurnaroundThese stocks have poor financials and average valuation and momentum. Investors should be cautious about these stocksView Similar Embed DVM

Analyst Price Target

No estimates available

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

Medium rank

9Positive13Negative

40.9%Pass in checklist

045

100

Check P/E Buy Sell Zone

Buy Zone

37.0 % into P/E buy sell zone

% time spent below current P/E

020406080100

Strong upside potential

Gains already realized

Sudarshan Pharma Stock Price Analysis

Day Price Range -1.3% 1 Day return	35.4 (LTP) 34.638 LowHigh
Week Price Range 13.2% 1 Week return	35.4 (LTP) 2939.4 LowHigh
Month Price Range -5.0% 1 Month return	35.4 (LTP) 2939.4 LowHigh
52 Week Price Range 30.9% 1 Year return	35.4 (LTP) 18.542.8 LowHigh

View full Price History/Seasonality

Competitors/Peers

Quarterly

Annual

Balance Sheet

Ratios

Cash Flow

Documents

Sudarshan Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue Sudarshan Pharma Mar-2026 Annual Revenue is Rs 676 Cr which is growth of 33.7% YoY.
POSITIVE
Annual Net Profit Sudarshan Pharma Mar-2026 Annual Net Profit is Rs 22 Cr which is growth of 38.4% YoY.

Sudarshan Pharma Industries Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17
SR_A Total Rev. Ann. ⌄	13.5%	28.4%	737	675.9	505.4	468.3	462.5	357.6	193.6	148	140	89.8	55.5
TotalOperatingRevenues_A Operating Rev. Ann.	13.1%	28.1%	728.9	667.5	502.5	465.6	461.3	357.1	193.4	148	140	89.7	55.5
OI_A Other Income Ann.	96.9%	94.7%	8.1	8.4	2.9	2.8	1.1	0.5	0.3	0	0	0.1	0.1
OEXPNS_A Operating Exp. Ann.	11.5%	27.1%	662.8	618.5	464	443	446.6	346.2	186.2	143.4	134.9	87.6	54.8
OEXPNS_A Operating Exp. Ann.	11.5%	27.1%	662.8	618.5	464	443	446.6	346.2	186.2	143.4	134.9	87.6	54.8
OP_A Operating Profit Ann.	49.4%	46.7%	66	49	38.5	22.6	14.7	10.9	7.2	4.6	5.2	2.1	0.7
OPMPCT_A OPM Ann. %	31.6%	14.3%		7.24%	7.62%	4.83%	3.18%	3.05%	3.71%	3.11%	3.68%	2.34%	1.24%
TotalExpenses_A Total Exp. Ann. ⌄	12.6%	27.8%		647.2	481.3	453.2	453	350.4	190	146.3	136.8	88.8	55.3
OtherExpenses_A Other Exp. Ann.	73.4%	35.3%	32.3	24	10	5.8	4.6	3.1	5.3	3.9	2.5	2.1	1.5
EmployeeBenefitExpenses_A Employee Exp. Ann.	27.4%	31.1%	7	6.2	4.6	3.5	3	2.4	1.6	1.6	2.5	2.3	0.8
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	53.7%	50.2%		57.4	41.4	25.4	15.8	11.4	7.5	4.6	5.2	2.2	0.7
EBIDTPCT_A EBITDA Ann. margin %	35.4%	17.1%		8.49%	8.19%	5.41%	3.42%	3.18%	3.85%	3.13%	3.69%	2.46%	1.33%
INT_A Interest Ann.	67.3%	52.2%	32.1	25.3	16	9	5.4	3.4	3.1	2.6	1.8	1.2	0.4
DEP_A Depr.	55.7%	37.2%	4.4	3.4	1.3	1.2	0.9	0.9	0.7	0.4	0.2	0.1	0.1
PBT_A PBT Ann.	44.6%	51.5%	37.7	28.7	21.3	15.1	9.5	7.1	3.6	1.7	3.3	1	0.3
TAX_A Tax Ann.	38.9%	49.4%	10	6.7	5.4	3.7	2.5	1.9	0.9	0.4	0.9	0.3	0.1
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	46.5%	52.1%		22	15.9	11.4	7	5.3	2.7	1.3	2.4	0.7	0.2
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	46.5%	52.1%	27.7	22	15.9	11.4	7	5.3	2.7	1.3	2.4	0.7	0.2
NETPCT_A NPM Ann. %	29.4%	19%		3.29%	3.15%	2.43%	1.52%	1.47%	1.38%	0.86%	1.67%	0.82%	0.28%
EPS_adj_A EPS Adj. latest Ann.	44.2%	55.2%		0.9	0.7	0.5	0.3	0.2	0.1	0.1	0.1	0	0
result_notes Result Notes				Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

VIEW ALL TABLE IN FINANCIAL PAGE

Total Rev. Ann.

1Y CHG

33.7%

2Y CAGR

20.1%

3Y CAGR

13.5%

5Y CAGR

28.4%

7Y CAGR

25.2%

Total Revenue Annual growth is higher than historical averages.

Net Profit Ann.

1Y CHG

38.4%

2Y CAGR

38.9%

3Y CAGR

46.5%

5Y CAGR

52.1%

7Y CAGR

37.2%

Net Profit Annual growth is stable compared to historical averages.

Operating Exp. Ann.

1Y CHG

33.3%

2Y CAGR

18.2%

3Y CAGR

11.5%

5Y CAGR

27.1%

7Y CAGR

24.3%

Operating Expenses Annual Cr growth is higher than historical averages.

Sudarshan Pharma Technical Analysis

Sudarshan Pharma EMA & SMA

Bearish-6

1 bullish, 7 bearish

Bullish1

Bearish7

5 Day	35.6
10 Day	35.4
12 Day	35.5
20 Day	35.9

26 Day	36.2
50 Day	36.9
100 Day	36.4
200 Day	34.3

Sudarshan Pharma Delivery And Volume

Daily Avg. Delivery Volume %

02 Nov, 202660.2%

Week59.2%

Month77.4%

Legend

Positive IndicatorNeutral IndicatorNegative Indicator

Sudarshan Pharma Resistance and Support

35.98

Pivot

First Resistance	37.4
Second Resistance	39.4
Third Resistance	40.9

First Support	34.0
Second Support	32.5
Third Support	30.5

Day RSI	47
Day MACD	-0.7
Day MFI	17
Day MACD Signal Line	-0.9

Sudarshan Pharma Beta

1 Month	1.1
1 Year	0.8

3 Month	0.5
3 Year	0.5

Sudarshan Pharma Price Change Analysis

↓-5.0%

Over 1 Month

LowHigh

29.039.4

↓-6.6%

Over 3 Months

LowHigh

29.042.5

↑16.9%

Over 6 Months

LowHigh

27.842.8

↑30.9%

Over 1 Year

LowHigh

18.542.8

Sudarshan Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026

Name	Category	Shares	Shares %
Sachin Vasantrai Mehta	Promoter	70,705,470	27.8 %
Century India Opportunity Fund Pc	Fii	8,100,000	3.2 %
Saumik Ketankumar Doshi	Public	7,200,000	2.8 %

HISTORICAL PROMOTER HOLDING

Promoters have decreased holdings from 58.93% to 57.81% in Sep 2026 qtr

Promoters pledged 21.90% of shares in last quarter. Total pledge stands at 23.26% of promoter holdings

HISTORICAL FII HOLDING

FII/FPI have increased holdings from 19.38% to 21.94% in Sep 2026 qtr.

HISTORICAL MF HOLDING

All Shareholding details

Sudarshan Pharma Deals - Insider, Bulk, Block and SAST

Client Name	Deal Type	Action	Date	Avg. Price	Quantity	Exchange
NORTH STAR OPPORTUNITIES FUND VCC-BULL VALUE INCORPORATED VCC SUB-FUND	Bulk	Purchase	11 Feb 2025	35.73	1,500,000	BSE
SETU SECURITIES PVT LTD	Bulk	Purchase	01 Jan 2025	44.35	1,248,000	BSE
MANSI SHARE & STOCK ADVISORS PRIVATE LIMITED	Bulk	Sell	01 Jan 2025	44.35	1,248,000	BSE
CENTURY INDIA OPPORTUNITY FUND PC	Bulk	Purchase	28 Nov 2024	41.97	1,600,000	BSE
SAROJ GUPTA	Bulk	Purchase	25 Sep 2024	411	150,400	BSE
SAROJ GUPTA	Bulk	Sell	25 Sep 2024	424.35	75,200	BSE
EPITOME TRADING AND INVESTMENTS	Bulk	Sell	25 Sep 2024	421.92	153,600	BSE
EPITOME TRADING AND INVESTMENTS	Bulk	Purchase	25 Sep 2024	424.33	134,400	BSE
BISHWANATH PRASAD AGRAWAL	Bulk	Purchase	25 Sep 2024	412.41	139,200	BSE
EPITOME TRADING AND INVESTMENTS	Bulk	Sell	23 Sep 2024	381.48	52,800	BSE

All deals

Sudarshan Pharma Corporate Actions

Sudarshan Pharma Dividend history and yield

Sudarshan Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Sudarshan Pharma dividend yield over time.

#Ex-Date	Dividend Amount	Dividend Type	Record Date	Instrument Type
125 Aug 2023	0.3	FINAL	-	Equity Share

Sudarshan Pharma Board Meetings

Sudarshan Pharma past and upcoming board meetings.

#Ex-Date	Purpose	Notes
129 Oct 2026	Half Yearly Results & issue of Warrants	-
212 Aug 2026	Quarterly Results	-
318 Jun 2026	Issue Of Warrants	Inter-alia, to consider 1. Proposal for raising of funds by way of issue of one or more instruments through private placement / preferential issue or such method or combination thereof
421 May 2026	Others	(Revised) Inter-alia to consider 1. Approve Migration of listing / trading of the Equity Shares. 2. Approve Postal Ballot Notice & Calendat of events for seekirg approval. 3. Other business matters.
515 May 2026	Others	Inter-alia, to consider 1. The proposal for the issuance of Foreign Currency Convertible Bonds, subject to receipt of applicable regulatory and statutory approvals.

Sudarshan Pharma Stock Split

Sudarshan Pharma stock split details, including announcement, record, and ex-split dates, along with the split ratios

#Ex-Date	Old FV	New FV	Record Date
122 Nov 2024	10	1	23 Nov 2024

All Corporate Actions

Sudarshan Pharma Corporate Filings

Sudarshan Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

Date	Announcement Title	Details	Links
30 Oct 2026	Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Issue of Securities	In continuation of the Company''s letter dated 30/Oct/2026 (ref. no. SPIL/CS/2026-2027/72), the Board of Directors at its Meeting held on 29/Oct/2026 have approved the proposal to raising of funds through issue and allotment of Convertible Warrants upto an amount not exceeding Rs.72 Crores, each warrant convertible into 1 equity share of Re1/- each, on a preferential basis to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company. The Warrants shall be issued at a price to be determined as per Regulation 164 of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.	PDF
30 Oct 2026	Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Issue of Securities	This is to inform you that the Board of Directors of the Company at its Board Meeting held on 29/Oct/2026 has approved the proposal to raising funds through issue and allotment of up to 72 Crores Warrants, each Warrant convertible into 1 Equity Share of the face value of Re.1/- each on a preferential basis to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company.	PDF
29 Oct 2026	Sudarshan Pharma Industries Ltd - 543828 - Financial Results For The Quarter Ended 30-Sep-2026	We are submitting the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/Sep/2026	PDF
26 Oct 2026	Sudarshan Pharma Industries Ltd - 543828 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Scheduled To Be Held On Thursday, 29Th October, 2026	Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve i) Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended 30-Sep-2026; ii) consider and approve proposal for raising of funds and other ancillary functions, subject to such statutory and regulatory approvals as may be necessary.	PDF
23 Oct 2026	Sudarshan Pharma Industries Ltd - 543828 - Updates On Migration From SME Platform Of BSE To Capital Market Segment (Main Board) Of National Stock Exchange Of India Limited Of Sudarshan Pharma Industries Limited - Company Letter Bearing Ref. No. SPIL/CS/SE/2026-2027/20 Dated 21St May 2026	We are pleased to inform you that the Company ahs received letter from National Stock Exchange of India Limited dated 23-Oct-2026 stating that the equity shares of the Company shall be listed and admitted to dealings on the Exchange (Capital Market segment) w.e.f. 27-Oct-2026 pursuant to migration from SME platform of BSE Limited.	PDF

VIEW ALL

Sudarshan Pharma DocumentsAsk MarketMind AI

Sudarshan Pharma Annual Reports

Sudarshan Pharma financials, including annual results, balance sheets, and cash flow statements.

Date	Report Title	Links
2026	Annual Report Mar-2026	Link
2026	Annual Report Mar-2026	Link
2025	Annual Report Mar-2025	Link
2024	Annual Report Mar-2024	Link
2023	Annual Report Mar-2023	Link

Sudarshan Pharma Credit Ratings

Sudarshan Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

Date	Rating Agency	Company Name	Description	Links
22 Sep 2026	crisil ratings	Sudarshan Pharma Industries Limited	Sudarshan Pharma Industries Limited:Update on Sudarshan Pharma Industries Limited	Link
20 Aug 2026	crisil ratings	Sudarshan Pharma Industries Limited	Sudarshan Pharma Industries Limited:Update on Sudarshan Pharma Industries Limited	Link
29 Apr 2026	crisil ratings	Sudarshan Pharma Industries Limited	Sudarshan Pharma Industries Limited:'Crisil BBB / Stable / Crisil A3+ ' assigned to Bank Debt	Link
29 Jul 2025	brickwork ratings	Sudarshan Pharma Industries Ltd.	Issuer did not cooperate; Based on best available information; Outstanding Ratings are Reaffirmed and Withdrawn;	Link
17 Jul 2025	brickwork ratings	Sudarshan Pharma Industries Ltd.	Issuer did not cooperate; Based on best available information; Rating moved to Not Reviewed Advisory;

Sudarshan Pharma Investor Presentations

Sudarshan Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

Date	Report Title	Links
18 Aug 2026	Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Investor Presentation	Link
14 Aug 2026	Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Investor Presentation	Link
15 May 2026	Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Investor Presentation	Link
31 Jan 2026	Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Investor Presentation	Link
14 Aug 2025	Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Investor Presentation	Link

Sudarshan Pharma - Company Profile

Sudarshan Pharma Management Structure

Sudarshan Pharma management structure with salaries, total experience, and qualifications.

NAME	DESIGNATION	GROSS REMUNERATION ₹(LAC)	AS OF
NIRAV KISHOR KUMAR SHAH	Company Secretary,Compliance Officer	-	Mar 25
Mr. Manoj Lodha	Chief Financial Officer	-	Mar 25
Dr. Vishwas Joshi	Vice President(Technical)	-	Mar 25
Dr. Tapas Kumar Nandi	Vice President(Technical)	-	Mar 25

Sudarshan Pharma Board of Directors

Sudarshan Pharma Board of directors with salaries, total experience, and qualifications.

NAME	POSITION	GROSS REMUNERATION ₹(LAC)	AS OF
Hemal V Mehta	CMD & Director.	72	Mar 25
Sachin V Mehta	ED / Joint MD / CFO / Promoter	72	Mar 25
Rushabh Prashant Patil	Independent Non Exe. Director	1.8	Mar 25
Umesh Luthra	Independent Non Exe. Director	1.37	Mar 25
JAYA ANKUR SINGHANIA	Independent Non Exe. Director	1.32	Mar 25
ANIL BALKRISHNA GHOGARE	Non-Exec & Non-Independent Dir	0.54	Mar 25
NIRAV KISHOR KUMAR SHAH	Company Sec. & Compli. Officer	-	Mar 25

About

Website: www.sudarshanpharma.com

About the company - Business Profile

Sudarshan Pharma Industries Ltd. is an integrated pharmaceutical organization primarily engaged in the manufacturing and supply of specialty chemicals, intermediates, and Active Pharmaceutical Ingredients (APIs). The company operates across the pharmaceutical value chain, from research and development to the production of finished dosage forms (FDFs). It focuses on high-growth therapeutic areas, notably vitamins and APIs, and serves a diverse clientele in the pharmaceutical, agrochemical, and coating industries.

Key Points

Key Facts: The company was incorporated in 2008 (originally as Sudarshan Speciality Chemsolve Private Limited) and is headquartered in Mumbai, India. It is listed on the BSE (Stock Code: 543828) and NSE (Stock Code: SPIL).
Operations and Resources: Sudarshan Pharma operates through multiple manufacturing facilities, including a bulk drug and intermediate unit in Hyderabad and a production facility in Jejuri. The company recently expanded its manufacturing footprint by acquiring an operational facility from Srigen Lifesciences in Telangana for ₹25.50 crore.
Market and Significance: The company maintains a strong market presence in five Indian states and is actively expanding its international footprint, particularly in African and Asian markets, through formulation registrations. Its esteemed clientele includes global and domestic giants such as Sandoz, Biocon, Cipla, Zydus, Takeda, Sun Pharma, and Asian Paints.
Revenue Breakdown: For the fiscal year ended March 31, 2025, the company reported a consolidated revenue from operations of ₹505.05 crore, compared to ₹463.54 crore in the previous year.
Financial Performance (Consolidated FY2024-25):
- Total Income: ₹507.57 crore
- EBITDA: ₹39.62 crore (a significant increase from ₹25.42 crore in FY24)
- Profit After Tax (PAT): ₹15.96 crore
- Net Worth: ₹131.48 crore
Business Model and Core Competencies: The company follows an upward integration model, transitioning from sourcing and indenting to in-house manufacturing and R&D. It is skilled at providing customized solutions for drug intermediates and specialty chemicals. Key product offerings include branded generics like Jivan Kit, Setdown, Pulmo relief, Fix Pollen, and Flupimac.
Subsidiaries: Major units include Ratna Lifesciences (oncology APIs), Ishwari Healthcare (medical devices like sutures and catheters), and international arms like Sudarshan Pharma Industries Private Limited, Singapore and Cibachem General Trading LLC, Dubai.
Innovation and Sustainability: Sudarshan Pharma entered into a technology transfer agreement with Uttaranchal University in January 2025 to acquire rights for a patent focused on preparing bioplastic from rice stubble and Aloe Vera waste. The company is also investing in patent development at its new facilities.
Strategic Initiatives: The company is currently focused on increasing export volumes and optimizing margins in the local API resale market. It received approval for raising funds through Foreign Currency Convertible Bonds (FCCBs) up to $35 million to support growth and acquisition strategies.

References

Sudarshan Pharma FAQ

Sudarshan Pharma today is trading in the red, down by 1.28% at ₹35.38.

Sudarshan Pharma is currently trading down 1.28% on an intraday basis. In the past week the stock rose 13.22%. Stock has been down 6.62% in the past quarter and rose 30.89% in the past year. You can view this in the share price history/seasonality section.

Sudarshan Pharma is listed on NSE with the ticker SUDARSHAN and on BSE as 543828. It's currently trading on NSE at a share price of ₹35.38 and on BSE with a share price of ₹35.16.

The market cap of Sudarshan Pharma is ₹851.45 Cr. as of Nov 02, 2026.

Sudarshan Pharma announced a FINAL dividend of 3% which equals ₹0.3 in Aug 25, 2023.To view the full dividend history of Sudarshan Pharma click here.

Sudarshan Pharma has never issued bonus shares, but it has issued 1 stock split since its BSE/NSE listing. The latest announcement for Sudarshan Pharma stock split was on Nov 22, 2024 at a ratio of 10:1.

Sudarshan Pharma reported ₹218.9 Cr. in revenue, ₹8.09 Cr. in net profit, and ₹22.51 Cr. in EBITD as of Oct 29, 2026 for Q2 FY26-27.

There are no analyst predictions for stock price target for Sudarshan Pharma .

The PE ratio of Sudarshan Pharma is 36.54 as of Nov 02, 2026.

The PB ratio of Sudarshan Pharma is 5.3 as of Nov 02, 2026.

There are no analyst reports for Sudarshan Pharma .

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.

Key Metrics
DVM
Price Chart
Forecaster
Financials
Technicals
Shareholding
Deals
Documents
Corporate actions
Company Profile

Sudarshan Pharma Live Share Price Today, Share Analysis and Chart

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Sudarshan Pharma Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Sudarshan Pharma - Annual

Sudarshan Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Annual Revenue Sudarshan Pharma Mar-2026 Annual Revenue is Rs 676 Cr which is growth of 33.7% YoY.

Annual Net Profit Sudarshan Pharma Mar-2026 Annual Net Profit is Rs 22 Cr which is growth of 38.4% YoY.

Sudarshan Pharma Technical Analysis

Sudarshan Pharma EMA & SMA

Sudarshan Pharma Delivery And Volume

Sudarshan Pharma Resistance and Support

Sudarshan Pharma Beta

Sudarshan Pharma Price Change Analysis

Sudarshan Pharma Shareholding Pattern/ Ownership

Shareholding Summary

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

Sudarshan Pharma Deals - Insider, Bulk, Block and SAST

Bulk Block Deals

Sudarshan Pharma Corporate Actions

Sudarshan Pharma Dividend history and yield

Sudarshan Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Sudarshan Pharma dividend yield over time.

Sudarshan Pharma Board Meetings

Sudarshan Pharma past and upcoming board meetings.

Sudarshan Pharma Stock Split

Sudarshan Pharma stock split details, including announcement, record, and ex-split dates, along with the split ratios

Sudarshan Pharma Corporate Filings

Sudarshan Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

Sudarshan Pharma DocumentsAsk MarketMind AI

Sudarshan Pharma Annual Reports

Sudarshan Pharma financials, including annual results, balance sheets, and cash flow statements.

Sudarshan Pharma Credit Ratings

Sudarshan Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

Sudarshan Pharma Investor Presentations

Sudarshan Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

Sudarshan Pharma - Company Profile

Sudarshan Pharma Management Structure

Sudarshan Pharma management structure with salaries, total experience, and qualifications.

Sudarshan Pharma Board of Directors

Sudarshan Pharma Board of directors with salaries, total experience, and qualifications.

About the company - Business Profile

Key Points

References

Sudarshan Pharma FAQ

How is Sudarshan Pharma today?

Sudarshan Pharma today is trading in the red, down by 1.28% at ₹35.38.

How has Sudarshan Pharma performed historically?

Sudarshan Pharma is currently trading down 1.28% on an intraday basis. In the past week the stock rose 13.22%. Stock has been down 6.62% in the past quarter and rose 30.89% in the past year. You can view this in the share price history/seasonality section.

What is the current share price of Sudarshan Pharma on NSE and BSE exchanges?

Sudarshan Pharma is listed on NSE with the ticker SUDARSHAN and on BSE as 543828. It's currently trading on NSE at a share price of ₹35.38 and on BSE with a share price of ₹35.16.

What is the market cap of Sudarshan Pharma ?

The market cap of Sudarshan Pharma is ₹851.45 Cr. as of Nov 02, 2026.

When did Sudarshan Pharma last pay a dividend, and what has its dividend history been?

Sudarshan Pharma announced a FINAL dividend of 3% which equals ₹0.3 in Aug 25, 2023.To view the full dividend history of Sudarshan Pharma click here.

Has Sudarshan Pharma issued any bonus shares or share splits recently?

Sudarshan Pharma has never issued bonus shares, but it has issued 1 stock split since its BSE/NSE listing. The latest announcement for Sudarshan Pharma stock split was on Nov 22, 2024 at a ratio of 10:1.

What do the financial statements and annual reports of Sudarshan Pharma Indicate?

Sudarshan Pharma reported ₹218.9 Cr. in revenue, ₹8.09 Cr. in net profit, and ₹22.51 Cr. in EBITD as of Oct 29, 2026 for Q2 FY26-27.

What is the target share price of Sudarshan Pharma according to analyst predictions in FY26-27?

There are no analyst predictions for stock price target for Sudarshan Pharma .

What is the PE Ratio of Sudarshan Pharma ?

The PE ratio of Sudarshan Pharma is 36.54 as of Nov 02, 2026.

What is the PB Ratio of Sudarshan Pharma ?

The PB ratio of Sudarshan Pharma is 5.3 as of Nov 02, 2026.

Where can I check the latest Research Reports about Sudarshan Pharma ?

There are no analyst reports for Sudarshan Pharma .

How can I be notified of real time alerts about Sudarshan Pharma stock?

You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.